NOTVQ Market Analysis
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 3.72
- PEG ratio
- —
- P/B
- 0.01
- P/S (TTM)
- 0.00
- EV/EBITDA
- 68.66
Profitability & growth
- ROE (TTM)
- -74.1%
- Operating margin
- -16.0%
- Revenue growth YoY
- -5.4%
- Dividend yield
- —
- Beta
- 3.92
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Inotiv, Inc.
Company profileInotiv, Inc. (NOTVQ) is a prominent preclinical contract research organization that provides essential drug development and safety assessment services tailored for the biotech and pharmaceutical industries. The company offers a diverse array of solutions, including nonclinical imaging, pharmacology, and toxicology, which are critical in advancing the development of innovative therapeutics. With a focus on leveraging cutting-edge technologies and a highly competent workforce, Inotiv effectively delivers actionable insights that accelerate drug discovery processes. Positioned strategically…
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 2701 KENT AVENUE, WEST LAFAYETTE, IN
- Fiscal year end
- September
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer